Volume : 13, Issue : 04, April – 2026
Title:
ROLE OF PHARMACIST IN PROMOTING RATIONAL USE OF ORAL HYPOGLYCEMIC AGENTS IN DIABETES MELLITUS: REVIEW ARTICLE
Authors :
Pinninti.Swathi*, Saba Mubeena, K.Supriya, E.Sreeja*, Dr. P.somasekhar
Abstract :
Background: Diabetes mellitus (DM) is a chronic metabolic disorder of pandemic proportions, affecting over 537 million adults globally as of 2021, with projections exceeding 783 million by 2045. Management of type 2 DM (T2DM) relies heavily on oral hypoglycemic agents (OHAs); however, suboptimal prescribing, non-adherence, and drug-related problems remain significant barriers to achieving therapeutic goals.
Objective: This review examines the multifaceted role of the pharmacist in promoting the rational use of OHAs in DM, with emphasis on evidence-based interventions that improve clinical, humanistic, and economic outcomes.
Literature Review: A narrative review of literature published predominantly between 2015 and 2025 was conducted using PubMed, MEDLINE, Embase, Cochrane Library, and ScienceDirect. International guidelines from the WHO, ADA, and IDF were incorporated. Studies assessing pharmacist-led interventions in T2DM management, including randomized controlled trials, systematic reviews, and meta-analyses, were included.
Results: Pharmacist-led interventions — encompassing patient counselling, medication therapy management (MTM), adherence support, drug interaction monitoring, and pharmacovigilance — consistently demonstrate significant reductions in HbA1c (0.5–1.2%), improvements in blood pressure and lipid profiles, and enhanced patient quality of life. Collaborative pharmacist–physician models demonstrate an 85% physician acceptance rate for pharmacist recommendations.
Conclusion: Pharmacists are indispensable members of the diabetes care team. Expanding their clinical roles, embedding them in collaborative practice models, and addressing systemic barriers are essential for achieving rational OHA use and optimal patient outcomes in DM.
Keywords: Pharmacist; rational drug use; oral hypoglycemic agents; diabetes mellitus; medication therapy management; adherence; pharmacovigilance; clinical outcomes; collaborative practice; type 2 diabetes.
Cite This Article:
Please cite this article in press P.Swathi et al., Role Of Pharmacist In Promoting Rational Use Of Oral Hypoglycemic Agents In Diabetes Mellitus: Review Article, Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021. Available from: https://www.diabetesatlas.org
2. American Diabetes Association. Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140–S157.
3. Pousinho S, Morgado M, Plácido AI, Roque F, Falcão A, Alves G. Clinical pharmacists’ interventions in the management of type 2 diabetes mellitus: a systematic review. Pharm Pract. 2020;18(3):1–9.
4. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials. J Managed Care Specialty Pharm. 2016;22(5):493–515.
5. Linawati Y, Kristin E, Prabandari YS, Kristina SA, Pinzon RT. Pharmacist-led interventions for type 2 diabetes mellitus: a systematic review. Int J Pharm Res. 2021;13(02):1–10.
6. Alabkal RM, Medlinskiene K, Silcock J, Graham A. Impact of pharmacist-led interventions to improve clinical outcomes for adults with type 2 diabetes at risk of developing cardiovascular disease: a systematic review and meta-analysis. J Pharm Pract. 2023;36(4):888–899.
7. World Health Organization. The rational use of drugs: report of the Conference of Experts, Nairobi 1985. Geneva: WHO; 1987.
8. Attipoe A, Santi A, Verrue C, et al. Therapeutic impact of an intervention associating pharmacist counseling and the use of a mobile health application for type 2 diabetes patients. Int J Integr Care. 2023;23(S1):345.
9. Abdulrhim S, Sallom H, Al-Hussain F, Hussain MA, Awaisu A, Mahfoud ZR, et al. Impact of pharmacist interventions on health outcomes of patients with type 2 diabetes mellitus in the Middle East: a systematic review. J Diabetes Metab Disord. 2025. doi:10.1186/s40200-025-01521-1.
10. El-Osta A, Webber D, Gnani S, et al. The self-management patient education programme for diabetes mellitus: a systematic review. Prim Care Diabetes. 2013;7(2):91–100.
11. Zhu LY, Chen LJ, Sun XY, et al. The effectiveness and cost-effectiveness of pharmacist-led interventions for patients with type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1–15.
12. Pharmaceutical Care Network Europe (PCNE). Classification of drug-related problems V9.1. Zuidlaren: PCNE; 2020. Available from: https://www.pcne.org
13. Al Hamarneh YN, Tsuyuki RT, Jones CA, et al. Effectiveness of pharmacist interventions on cardiovascular risk in patients with type 2 diabetes: the Diabetes Continuity of Care (D-COP) randomized controlled trial. Can J Diabetes. 2017;41(6):580–586.
14. ElSayed NA, Aleppo G, Aroda VR, et al. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S68–S96.
15. Sallom H, Abdi A, Halboup AM, Basgut B. Evaluation of pharmaceutical care services in the Middle East countries: a review of studies of 2013–2020. J Pharm Policy Pract. 2021;14(1):72.